Cardiovascular safety review for osteoporosis drug

The TGA has commenced a cardiovascular safety review for the osteoporosis drug strontium ranelate (Protos) following a move by  European drug regulators to ban the drug because of its potential cardiac risks.

On 4 February the TGA announced that it was undertaking a review of Protos “ to assess the risk of adverse events including cardiovascular events.”